Patents by Inventor Daniel G. Brenner
Daniel G. Brenner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130117871Abstract: Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.Type: ApplicationFiled: July 30, 2012Publication date: May 9, 2013Inventors: Raju Kucherlapati, Aya Jakobovits, Daniel G. Brenner, Daniel J. Capon, Sue Klapholz
-
Publication number: 20120117669Abstract: Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.Type: ApplicationFiled: July 15, 2010Publication date: May 10, 2012Inventors: Raju KUCHERLAPATI, Aya Jakobovits, Daniel G. Brenner, Daniel J. Capon, Sue Klapholz
-
Publication number: 20100010202Abstract: Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.Type: ApplicationFiled: August 20, 2007Publication date: January 14, 2010Inventors: Raju Kucherlapati, Aya Jakobovits, Daniel G. Brenner, Daniel J. Capon, Sue Klapholz
-
Publication number: 20090149637Abstract: Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.Type: ApplicationFiled: August 8, 2007Publication date: June 11, 2009Inventors: Raju Kucherlapati, Aya Jakobovits, Daniel G. Brenner, Daniel J. Capon, Sue Klapholz
-
Publication number: 20040093622Abstract: The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.Type: ApplicationFiled: July 24, 2003Publication date: May 13, 2004Applicant: Abgenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G. Brenner, Daniel J. Capon
-
Patent number: 6713610Abstract: Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.Type: GrantFiled: July 11, 2000Date of Patent: March 30, 2004Inventors: Raju Kucherlapati, Aya Jakobovits, Daniel G. Brenner, Daniel J. Capon, Sue Klapholz
-
Publication number: 20040010810Abstract: The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.Type: ApplicationFiled: June 4, 2003Publication date: January 15, 2004Applicant: ABGENIX, INC.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G. Brenner, Daniel J. Capon
-
Patent number: 6673986Abstract: The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.Type: GrantFiled: March 15, 1993Date of Patent: January 6, 2004Assignee: Abgenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G. Brenner, Daniel J. Capon
-
Publication number: 20030229905Abstract: The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.Type: ApplicationFiled: April 21, 2003Publication date: December 11, 2003Applicant: Abqenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G. Brenner, Daniel J. Capon
-
Patent number: 6657103Abstract: Antibodies with fully human variable regions against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.Type: GrantFiled: September 4, 1997Date of Patent: December 2, 2003Assignee: Abgenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G. Brenner, Daniel J. Capon
-
Patent number: 6162963Abstract: The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.Type: GrantFiled: June 5, 1995Date of Patent: December 19, 2000Assignee: Abgenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G. Brenner, Daniel J. Capon
-
Patent number: 6150584Abstract: Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.Type: GrantFiled: October 2, 1996Date of Patent: November 21, 2000Assignee: Abgenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Daniel G. Brenner, Daniel J. Capon, Sue Klapholz
-
Patent number: 6114598Abstract: The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.Type: GrantFiled: June 5, 1995Date of Patent: September 5, 2000Assignee: Abgenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Kalpholz, Daniel G. Brenner, Daniel J. Capon
-
Patent number: 6075181Abstract: Antibodies with fully human variable regions against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.Type: GrantFiled: June 7, 1995Date of Patent: June 13, 2000Assignee: Abgenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G. Brenner, Daniel J. Capon
-
Patent number: 4256889Abstract: Benzocycloheptapyridines with an imine bridge in the cycloheptane ring, derivatives and pharmaceutically acceptable salts thereof are useful as anxiolytics, antidepressants, anticonvulsants, muscle relaxants and in the treatment of mixed anxiety-depression, minimal brain dysfunction and extrapyramidal disorders such as Parkinson's disease. They are prepared, for example, by treatment of a benzo[5,6]cyclohepta[1,2-c]pyridin-11-one with ammonia to give the 11-imine, acylation of the imine, treatment of the protected imine with an alkyllithium to provide the 11-alkyl-11-acylamino compound, treatment with acid or base to cause ring closure to an 11-alkyl-6,11-acylimino compound followed by removal of the protecting group, either hydrolytically or hydrogenolytically.Type: GrantFiled: November 13, 1979Date of Patent: March 17, 1981Assignee: Merck & Co., Inc.Inventors: Kenneth L. Shepard, Daniel G. Brenner
-
Patent number: 4232158Abstract: 10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines, derivatives and pharmaceutically acceptable salts thereof are useful as antianxiety agents, as muscle relaxants and in the treatment of extrapyramidal disorders such as in Parkinson's disease. They are prepared by treatment of a 5H-dibenzo[a,d]cyclohepten-5-one with ammonia to give the 5-imine, acylation of the imine, treatment of the protected imine with an organolithium to provide the 5-substituted-5-acylamino compound, treatment with acid or base to cause ring closure to a 5-substituted-5,10-acylimino compound followed by removal of the protecting group, either hydrolytically or hydrogenolytically.Type: GrantFiled: June 4, 1979Date of Patent: November 4, 1980Assignee: Merck & Co., Inc.Inventors: Kenneth L. Shepard, Daniel G. Brenner